BioPharma CreditLSE:BPCR +0.63%49 ROE % is 9.93% as of Dec. 2025, which is 18% above its 10-year median of 8.45. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,609 Asset Management companies, BioPharma Credit ranks better than 66.87% on this metric.
The historical rank and industry rank for BioPharma Credit's ROE % or its related term are showing as below:
LSE:BPCR'
s ROE % Range Over the Past 10 Years
Min: 6.09 Med: 8.45 Max: 13.5
Current: 11.19
During the past 9 years, BioPharma Credit's highest ROE % was 13.50%. The lowest was 6.09%. And the median was 8.45%.
LSE:BPCR's ROE % is ranked better than 66.87% of 1609
companies
in the Asset Management industry
Industry Median: 6.52
vs LSE:BPCR: 11.19
BioPharma Credit (LSE:BPCR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
BioPharma Credit ROE % Related Terms
BioPharma Credit ROE % Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit ROE % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's ROE % distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
BioPharma Credit (LSE:BPCR) has a ROE % of 9.93% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BioPharma Credit and its competitors. This is 18% above median its historical median of 8.45. Over the past decade, BioPharma Credit's ROE % has ranged from 6.09 to 13.50. According to the industry distribution chart, BioPharma Credit ranks #533 out of 1609 companies in the Asset Management industry, placing it in the top 33.1%.
Is BioPharma Credit's ROE % too high?
BioPharma Credit's current ROE % of 9.93% is 18% above median its 10-year median of 8.45. Over the past 10 years, this metric has ranged from a low of 6.09 to a high of 13.50. The Asset Management industry median ROE % is 6.52. BioPharma Credit's value of 9.93% is 52.3% above this industry median. Based on the distribution chart, BioPharma Credit ranks #533 out of 1609 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's ROE % compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #533 out of 1609 companies for ROE %. This puts BioPharma Credit in the upper half of its industry. The industry median ROE % is 6.52. BioPharma Credit's value of 9.93% is 52.3% above this benchmark. Historically, BioPharma Credit's own ROE % has ranged from 6.09 to 13.50 over the past decade. While the company's 10-year median is 8.45 vs. the industry median of 6.52, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for an Asset Management company?
The median ROE % among Asset Management companies is 6.52, based on 1,609 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current ROE % of 9.93% is 52.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median ROE % is 6.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current ROE % is 9.93%, which is 18% above median its own 10-year median of 8.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current ROE % is 9.93%, which is 18% above median its 10-year median of 8.45 and 52.3% above the Asset Management industry median of 6.52. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current ROE % is 9.93% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
ROE %: 9.93% (18% above median its 10-year median of 8.45)
GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
Industry Position: 52.3% above the Asset Management median (#533 of 1609)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score
Get the complete analysis for LSE:BPCR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
